Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide
Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide
Neha Gupta
Thu, February 19, 2026 at 5:43 PM GMT+9 2 min read
In this article:
PRAX
+0.27%
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the best stocks to buy and hold for the next 6 months. On February 10, Guggenheim raised its price target for Praxis Precision Medicines Inc. (NASDAQ:PRAX) to $800 from $760 while reiterating a Buy rating.
Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide
The research firm raised its price target, impressed by the significant market opportunity for ulixacaltamide, the company’s flagship treatment for essential tremor (ET). According to Guggenheim, Praxis Precision is well-positioned to capitalize on one of the largest and underpenetrated markets in neurology. The essential tremor market is valued at over $15 billion, and Praxis Precision is poised to achieve peak sales of $5- $10 billion with ulixacaltamide.
Earlier on January 28, Piper Sandler raised the stock’s price target to $1200 from $450 while maintaining an Overweight rating. The significant price target hike is in response to ulixacaltamide’s significant success in essential tremor. In addition, the research firm has touted progress in relutrigine and epileptic encephalopathies (DEEs). The research firm expects the company to achieve more than $20 billion in revenue with less than 5% peak market share.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into therapies for CNS disorders characterized by an imbalance between neuronal excitation and inhibition.
While we acknowledge the potential of PRAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Best High Return Penny Stocks to Buy Right Now and 10 High-Growth Low PE Stocks to Buy Now.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy
Privacy Dashboard
More Info